Session: Poster Session B Abstract title:Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and ...

DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions ...

Metsera is a clinical-stage biotechnology company developing injectable and oral treatments for obesity and related conditions, the filing shows. The company’s investors include affiliates of ...

The future of the Bay Area biotech firm Allakos was riding on one clinical trial, for a drug designed to treat the skin condition known as chronic spontaneous urticaria, or chronic hives.

Sam Altman, pictured at President Donald Trump's inauguration, is contributing to another round of funding for Retro Biosciences. © 2025 Fortune Media IP Limited ...

Only one traditional preclinical biotech—Metagenomi—went public last year, compared to around a quarter of the biotechs that IPOed in 2020 and 2021, according to Surti. About two-thirds of the ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics revealing plans to go public while Hong Kong-listed Ascentage Pharma joins ...

Canada has long punched above its weight in life sciences and biotechnology, with many of the fundamental discoveries that underpin today’s important blockbuster drugs and therapeutic approaches ...

EU targets AI, biotech, green tech, advance materials sectors Draghi report said EU is falling behind US and China France, Trump push EU to cut business red tape EU plans include 25% reduction of ...

Ascentage Pharma, a China-based drug developer with global ambitions, now has $126.4 million from a U.S. IPO that will mainly support late-stage clinical development of two medicines that could ...

Ascentage sold 7,325,000 American Depositary shares at $17.25 each. Credit: Andrey Zhuravlev via Getty Images. China-based biotech Ascentage Pharma has raised $126m in a US initial public offering ...

Rossari Biotech slipped 4.09% to Rs 769.40 after the specialty chemical maker reported 7.82% decline in consolidated net profit to Rs 31.70 crore in Q3 FY25 as against Rs 34.39 crore posted in Q3 FY24 ...